Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. / Brissot, Eolia; Labopin, Myriam; Beckers, Marielle M; Socié, Gérard; Rambaldi, Alessandro; Volin, Liisa; Finke, Jürgen; Lenhoff, Stig; Kröger, Nicolaus; Ossenkoppele, Gert J; Craddock, Charles F; Yakoub-Agha, Ibrahim; Gürman, Günhan; Russell, Nigel H; Aljurf, Mahmoud; Potter, Michael N; Nagler, Arnon; Ottmann, Oliver; Cornelissen, Jan J; Esteve, Jordi; Mohty, Mohamad.

I: Haematologica, Vol. 100, Nr. 3, 2015, s. 392-399.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Brissot, E, Labopin, M, Beckers, MM, Socié, G, Rambaldi, A, Volin, L, Finke, J, Lenhoff, S, Kröger, N, Ossenkoppele, GJ, Craddock, CF, Yakoub-Agha, I, Gürman, G, Russell, NH, Aljurf, M, Potter, MN, Nagler, A, Ottmann, O, Cornelissen, JJ, Esteve, J & Mohty, M 2015, 'Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.', Haematologica, vol. 100, nr. 3, s. 392-399. https://doi.org/10.3324/haematol.2014.116954

APA

CBE

Brissot E, Labopin M, Beckers MM, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele GJ, Craddock CF, Yakoub-Agha I, Gürman G, Russell NH, Aljurf M, Potter MN, Nagler A, Ottmann O, Cornelissen JJ, Esteve J, Mohty M. 2015. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 100(3):392-399. https://doi.org/10.3324/haematol.2014.116954

MLA

Vancouver

Author

Brissot, Eolia ; Labopin, Myriam ; Beckers, Marielle M ; Socié, Gérard ; Rambaldi, Alessandro ; Volin, Liisa ; Finke, Jürgen ; Lenhoff, Stig ; Kröger, Nicolaus ; Ossenkoppele, Gert J ; Craddock, Charles F ; Yakoub-Agha, Ibrahim ; Gürman, Günhan ; Russell, Nigel H ; Aljurf, Mahmoud ; Potter, Michael N ; Nagler, Arnon ; Ottmann, Oliver ; Cornelissen, Jan J ; Esteve, Jordi ; Mohty, Mohamad. / Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. I: Haematologica. 2015 ; Vol. 100, Nr. 3. s. 392-399.

RIS

TY - JOUR

T1 - Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.

AU - Brissot, Eolia

AU - Labopin, Myriam

AU - Beckers, Marielle M

AU - Socié, Gérard

AU - Rambaldi, Alessandro

AU - Volin, Liisa

AU - Finke, Jürgen

AU - Lenhoff, Stig

AU - Kröger, Nicolaus

AU - Ossenkoppele, Gert J

AU - Craddock, Charles F

AU - Yakoub-Agha, Ibrahim

AU - Gürman, Günhan

AU - Russell, Nigel H

AU - Aljurf, Mahmoud

AU - Potter, Michael N

AU - Nagler, Arnon

AU - Ottmann, Oliver

AU - Cornelissen, Jan J

AU - Esteve, Jordi

AU - Mohty, Mohamad

PY - 2015

Y1 - 2015

N2 - This study aimed to determine the impact of tyrosine-kinase inhibitors given pre- and post-allogeneic stem cell transplantation on long term outcome of patients allografted for Philadelphia chromosome-positive acute lymphoblastic leukemia. This retrospective analysis from the Acute Leukemia Working Party of EBMT included 473 de novo Philadelphia chromosome-positive acute lymphoblastic leukemia patients in first complete remission who underwent an allogeneic stem cell transplantation using an human leucocyte antigen-identical sibling or human leucocyte antigen-matched unrelated donor between 2000 and 2010. Three hundred ninety patients received tyrosine-kinase inhibitors before transplant, 329 at induction and 274 at consolidation. The Kaplan-Meier estimates of leukemia-free survival, overall survival, cumulative incidences of relapse incidence, and non-relapse mortality at 5 years were 38%, 46%, 36% and 26%, respectively. In multivariate analysis, tyrosine-kinase inhibitors given before allogeneic stem cell transplantation was associated with a better overall survival (HR=0.68; P=.04) and was associated with lower relapse incidence (HR=0.5; P=.01). In the post-transplant period, multivariate analysis identified prophylactic tyrosine-kinase inhibitors administration to be a significant factor for improved leukemia-free survival (HR=0.44; P=.002) and overall survival (HR=0.42; P=.004), and a lower relapse incidence (HR=0.40; P=.01). In conclusion, over the past decade, tyrosine-kinase inhibitors administration before allogeneic stem cell transplantation has significantly improved the long term allogeneic stem cell transplantation outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Prospective studies will be of great interest to further confirm the potential benefit of the prophylactic use of tyrosine-kinase inhibitors in the post-transplant setting.

AB - This study aimed to determine the impact of tyrosine-kinase inhibitors given pre- and post-allogeneic stem cell transplantation on long term outcome of patients allografted for Philadelphia chromosome-positive acute lymphoblastic leukemia. This retrospective analysis from the Acute Leukemia Working Party of EBMT included 473 de novo Philadelphia chromosome-positive acute lymphoblastic leukemia patients in first complete remission who underwent an allogeneic stem cell transplantation using an human leucocyte antigen-identical sibling or human leucocyte antigen-matched unrelated donor between 2000 and 2010. Three hundred ninety patients received tyrosine-kinase inhibitors before transplant, 329 at induction and 274 at consolidation. The Kaplan-Meier estimates of leukemia-free survival, overall survival, cumulative incidences of relapse incidence, and non-relapse mortality at 5 years were 38%, 46%, 36% and 26%, respectively. In multivariate analysis, tyrosine-kinase inhibitors given before allogeneic stem cell transplantation was associated with a better overall survival (HR=0.68; P=.04) and was associated with lower relapse incidence (HR=0.5; P=.01). In the post-transplant period, multivariate analysis identified prophylactic tyrosine-kinase inhibitors administration to be a significant factor for improved leukemia-free survival (HR=0.44; P=.002) and overall survival (HR=0.42; P=.004), and a lower relapse incidence (HR=0.40; P=.01). In conclusion, over the past decade, tyrosine-kinase inhibitors administration before allogeneic stem cell transplantation has significantly improved the long term allogeneic stem cell transplantation outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Prospective studies will be of great interest to further confirm the potential benefit of the prophylactic use of tyrosine-kinase inhibitors in the post-transplant setting.

U2 - 10.3324/haematol.2014.116954

DO - 10.3324/haematol.2014.116954

M3 - Article

VL - 100

SP - 392

EP - 399

JO - Haematologica-The Hematology Journal

T2 - Haematologica-The Hematology Journal

JF - Haematologica-The Hematology Journal

SN - 1592-8721

IS - 3

ER -